BioAge Labs, Inc.
Close on Oct 19, 2026
- Market cap
- $223.75M
- P/E (TTM)
- –
- Dividend yield
- –
About BioAge Labs
Pharmaceutical Preparations, SIC 2834
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic candidates for chronic metabolic diseases by targeting human aging biology. The company leverages a proprietary computational platform built on longitudinal human datasets and biobanked samples to identify molecular drivers of longevity and healthspan. Its lead product candidate, BGE-102, is an orally administered, brain-penetrant small-molecule NLRP3 inhibitor under development for cardiometabolic indications, particularly cardiovascular risk reduction in patients with obesity, and ophthalmology indications including diabetic macular edema. BioAge is also advancing apelin receptor agonists for obesity as well as earlier-stage discovery programs in collaboration with major pharmaceutical partners.
The company operates primarily through research and clinical trial collaborations, partnering on discovery and pipeline programs with firms such as Eli Lilly and Company, Novartis Pharma AG, and JiKang Therapeutics. BioAge conducts its clinical activities in clinical trial units and maintains discovery collaborations with academic institutions such as the University of Bonn. The company is co-founded and led by an executive management team based in North America.
Summary of the business section of BioAge Labs's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioAge Labs, Inc.
- Headquarters
- Emeryville, CA
- Address
- 5885 Hollis Street, Suite 370 94608
- Phone
- (510) 806-1445
- Website
- bioagelabs.com
- Employees
- 62, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, California
Stock & identifiers
- Ticker
- BIOA
- Exchange
- Nasdaq
- IPO date
- Sep 26, 2024
- Shares outstanding
- 46M, Jul 31, 2026
- Public float
- $112.70M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1709941
- CUSIP
- 09077V100
- ISIN
- US09077V1008
- LEI
- 529900NG0C40250Z7875
- EIN
- 47-4721157
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric Morgen | Chief Operating Officer, Director | 67,225 |
| Kristen Fortney | Chief Executive Officer, Director | 976,949 |
| Shane Barton | Principal Accounting Officer | 4,290 |
| Dov A. Goldstein Md | Chief Financial Officer | 36,575 |
| Paul D. Rubin | Chief Medical Officer | 0 |
| James Healy | Director | 2,304,901 |
| Jean Pierre Garnier | Director | – |
| Vijay Satyanand Pande | Director | 3,233,170 |
| Patrick G. Enright | Director | 1,710,589 |
| Michael H. Davidson | Director | – |
| Rekha Hemrajani | Director | 3,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 62 employees, 60 of whom were full-time and 44 of whom were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 26, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 18, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |